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I nr e c e n ty e a r s ,t h es t u d yo ft h ep e r o x i s o m ep r o l i f e r a t o r sa c t i v a t e dr e c e p t o rg a m m a( P P A R - γ) as a potential target for cancer
prevention and therapy has gained a strong interest. However, the overall biological signiﬁcance of PPAR-γ in cancer development
and progression is still controversial. While many reports documented antiproliferative eﬀects in human cancer cell and animal
models, several studies demonstrating potential tumor promoting actions of PPAR-γ ligands raised considerable concerns about
the role of PPAR-γ in human cancers. Controversy also exists about the role of PPAR-γ in human pancreatic cancers. The current
review summarizes the data about PPAR-γ in pancreatic cancer and highlights the biologically relevant interactions between the
cyclooxygenase and PPAR system.
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1. INTRODUCTION
Despite advances in surgical techniques, imaging modalities,
and intensive care, pancreatic cancer is still an almost
universally lethal disease with annual mortality ﬁgures
virtually equaling incidence numbers. An estimated number
of 37170 patients hse been diagnosed with pancreatic cancer
in 2007, and 33370 patients have succumbed to that disease
in the same year [1]. Absence of speciﬁc symptoms, lack
of early detection markers, aggressive tumor growth, and
virtual resistance to conventional chemo- and radiotherapy
conspire to culminate in a median overall survival of less
than nine months. Currently, surgical removal of the tumor
oﬀers the only hope of long-term survival with 5-year
survival rates approaching 25–30% in large-volume centers
in the US [2]. Although an adjuvant treatment regimen
after surgical resection seems to prolong survival, the precise
treatment protocol including drug-of-choice is still debated
and the focus of several ongoing clinical trials [3]. Only a
disappointing10–15%ofpatientsatthetimeofdiagnosisare
candidates for surgical resection and even patients who have
undergone “curative” resection often die of recurrent tumor.
The majority of pancreatic cancer patients unfortunately
present with locally advanced or metastatic tumors which
render them ineligible for surgical resection. Gem-citabine,
an S-phase nucleoside cytidine analog, has been the stan-
dard chemotherapeutic drug for locally advanced and
metastatic pancreatic cancer for more than ten years, but
the improvement of overall survival is unacceptably small,
often approaching only a few weeks [4]. Currently, sev-
eral trials are underway that investigate gemcitabine-based
combination therapiesin patients with advanced pancreatic
cancers. Capecitabine, an oral ﬂuoropyrimidine carbamate
and 5-ﬂuorouracil prodrug, and erlotinib, an inhibitor of
the epidermal growth factor receptor, are two promising
agents which seem to improve survival in combination with
gemcitabinecomparedtogemcitabinemonotherapy[4].The
encouraging results from a large, double-blind, placebo-
controlled, international phase III trial led to the approval of
erlotinibforthetreatmentoflocallyadvancedandmetastatic
pancreatic cancer in combination with gemcitabine [5].
Although certainly noteworthy, the improvement of over-
all survival with the combination regimen, however, was
only marginal compared to gemcitabine monotherapy [5],
strongly emphasizing the need for the identiﬁcation of novel
targets and the development of more eﬃcacious therapeutic
agents.
Although several environmental risk factors for the
development of pancreatic cancers, including tobacco smok-
inganddietaryfactors,havebeendescribed,detailedinsights2 PPAR Research
into the pathogenetic mechanisms are virtually lacking
[6]. Dietary intake of high-caloric, high-fat diets with
ensuing obesity and metabolic syndrome has been correlated
with an increased risk of pancreatic cancer [7, 8]. An
important molecule in fatty acid sensing and metabolism
is the peroxisome proliferator activated receptor gamma
(PPAR-γ) ,am e m b e ro ft h en u c l e a rr e c e p t o rs u p e r f a m i l y
that functions as a ligand-activated transcription factor [9].
There is now a large body of evidence demonstrating an
important role of PPAR-γ in the metabolic syndrome [10–
13]. The thiazolidinedione (TZD) class of PPAR-γ ligands
has been used for the treatment of hyperglycemia and
insulin resistance in type 2 diabetes for the past ten years
[14]. In addition, TZDs may also show beneﬁcial eﬀects
on cardiovascular complications associated with type 2
diabetesandthemetabolicsyndrome[14–17].Morerecently,
the role of PPAR-γ in various human cancers has been
studied. There is now strong evidence that PPAR-γ is
overexpressed in a variety of cancers, including colon, breast,
p r o s t a t e ,s t o m a c h ,l u n g ,a n dp a n c r e a s[ 18–20]. However, the
biological signiﬁcance of PPAR-γ is still controversial [21,
22]. Although several reviews highlight the antiproliferative
actions of PPAR-γ ligands in cell culture and animal models
of human cancers [23, 24], more recent studies illustrating
a tumor-promoting eﬀect of PPAR-γ,i np a r t i c u l a ri nc o l o n
and breast cancer models, raise considerable concern about
the signiﬁcance and safety of PPAR-γ ligands as anticancer
drugs [25–29]. This review will summarize and discuss the
data concerning the role of PPAR-γ in pancreatic cancer.
2. PPAR-GAMMA IN PANCREATIC CANCER
Reports from several groups have shown that the thiazo-
lidinedione (TZD) class of PPAR-γ ligands attenuates the
growth of pancreatic cancer cells in vitro by induction
of terminal diﬀerentiation and G1 phase cell cycle arrest
[30, 31], and by an increase in apoptotic cell death [32].
Furthermore, thiazolidinediones attenuated pancreatic can-
cer cell migration and invasion by modulation of actin
organization and expression of matrix metalloproteinase-2
and plasminogen activator inhibitor-1, respectively [33, 34].
However, many growth-inhibitory eﬀects of PPAR-γ ligands
are independent of PPAR-γ [35]. To date, several non-
PPAR-γ targets have been implicated in the antitumor
activities of certain TZDs, for example, troglitazone and
ciglitazone, including intracellular Ca2+ stores, mitogen-
activated protein kinases, cyclin-dependent kinase inhibitors
p27kip1 and p21WAF/CIP1, the tumor suppressor protein
p53, and Bcl-2 family members [36]. There is increasing
evidence that TZDs directly aﬀect mitochondrial function
which impairs oxidative respiration leading to increased
reactive oxygen species (ROS) production and ATP deple-
tion, which in turn can activate AMP kinase [37]. An
increase in ROS and activation of AMP kinase can lead to
PPAR-γ independent reduction in inﬂammation and cell
growth [37]. In addition, it has been shown in pancre-
atic cancer cells that 2-cyano-3,12-dioxooleana-1,9-dien-28-
imidazolide (CDDO-Im), a partial PPAR-γ agonist, induces
apoptosis directly by targeting mitochondrial glutathione
[38]. Furthermore, 3,3 -diindolylmethane (DIM), another
PPAR-γ agonist, induced apoptotic cell death in pancreatic
cancer cells through activation of the endoplasmic stress
response [39]. Overall, the potential to elicit PPAR-γ-
independent eﬀects may be ligand- and cell context-
dependent.OurownstudieshavedemonstratedthatPPAR-γ
is expressed in the nucleus of six human pancreatic cancer
cells and that treatment of these cells in vitro with 15-deoxy-
Δ12,14-prostaglandin J2 (15-PGJ2) and ciglitazone dose- and
time-dependently decreases cell growth by induction of
caspase-3-dependent apoptosis [40]. In addition to their
antiproliferative actions, both ligands, 15-PGJ2 and cigli-
tazone, reduced the invasive capacity of pancreatic cancer
cells in vitro by a PPAR-γ-mediated decrease of urokinase-
type plasminogen activator and elevation of plasminogen
activator inhibitor-1 expression that resulted in an overall
reduction in urokinase activity [41]. Taken together, there
is a strong evidence today from cell culture models that
PPAR-γ ligands potently reduce the growth of human
pancreatic cancer cells. The discrepancy of the reported
underlying mechanisms, however, may be caused by the use
of diﬀerent cell lines, culture conditions, and experimental
settings. In contrast to the notion of PPAR-γ ligands being
potent antitumor drugs in pancreatic cancers, we have
reported that treatment of human pancreatic cancer cells
in vitro with 15-PGJ2 and troglitazone dose-dependently
increases the secretion of the vascular endothelial growth
factor (VEGF), which is widely recognized as a potent
stimulus for tumor angiogenesis [42]. In addition, the
culture medium of troglitazone-treated human pancreatic
cancer cells enhanced migration of endothelial cells, another
step in the angiogenic cascade (own ﬁnding). These ﬁndings
are already observed at submicromolar concentrations of
the PPAR-γ ligands, which are usually considerably lower
than the typical ligand concentrations needed for the
antiproliferative eﬀects in pancreatic cancer cells. Our in
vitro data suggest that PPAR-γ ligands may have a tumor-
promoting eﬀect in vivo by enhancing tumor angiogenesis.
Although the precise role of PPAR-γ in tumor angiogenesis
is still debated and controversial, there is accumulating
evidence that activation of PPAR-γ stimulates VEGF pro-
duction and neoangiogenesis also in other cell models
[43, 44].
InadditiontotheeﬀectsofPPAR-γ ligandsonthegrowth
of established pancreatic cancers in preclinical cell culture
and xenograft mouse models, dietary intake of 800 ppm
pioglitazonefor22weekscorrelatedwithanimprovedserum
lipid proﬁle and a decreased incidence and multiplicity of
pancreatic tumors in the N-nitrosobis(2-oxopropyl)amine
(BOP) model of pancreatic carcinogenesis in Syrian golden
hamsters, suggesting a potential chemopreventive role of
TZDs [45].
There are very few data concerning the signiﬁcance of
PPAR-γ in clinical pancreatic cancer specimens. In a recent
study, PPAR-γ was expressed in the majority of human pan-
creatic cancer specimens, positively correlated with higher
tumor stage and grade, and interestingly was associated
with shorter patient survival, suggesting a potential role in
pancreatic cancer progression [20].Guido Eibl 3
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Figure 1: Possible interactions between the COX-2 and PPAR-γ
pathways: polyunsaturated fatty acids (PUFAs) are substrates for
cyclooxygenase-2 (COX-2) enzymes leading to the formation of
various prostaglandins (PGs). Certain PUFAs and PGs can also
activatePPAR-γ.Selective andnonselectiveCOX-2inhibitors(COX
Inh) block PG formation by COX-2 but can also at higher
concentrations activate PPAR-γ. Solid arrows indicate activation;
dashed arrow indicates metabolic pathway; blocked arrow indicates
inhibition.
3. INTERACTION BETWEEN THE PPAR-GAMMA
AND COX-2 PATHWAYS
Besides the TZD class of antidiabetic drugs, various intra-
cellular lipids and lipid mediators are capable of activating
PPAR-γ. Among those, polyunsaturated fatty acids (e.g.,
arachidonic acid (AA) and eicosapentaenoic acid (EPA))
and eicosanoids (e.g., 15-deoxy-Δ12,14-prostaglandin J2 (15-
PGJ2))arealsosubstratesandproducts,respectively,ofintra-
cellular cyclooxygenase (COX) enzymes strongly suggesting
relevant interactions between the PPAR and COX pathways
(see Figure 1).
3.1. COXproductsasPPAR-γ activators
COX activity leads to the formation of an unstable hydroxy-
endoperoxide, prostaglandin H2, which can be further
converted to various prostanoid species by tissue speciﬁc
isomerases [46]. While parent prostaglandins (e.g., PGE2,
PGF2α,a n dP G D 2) transduce their signals through binding
to G-protein coupled cell surface receptors [47], cyclopen-
tenoneprostanoids(e.g.,PGJ2)areknownligandsofPPAR-γ
[48]. In fact, there is evidence suggesting that COX-2 is
preferentially located on the nuclear membrane allowing
cyclopentenone prostaglandins to directly enter the nucleus
and bind to ligand-activated transcription factors [49]. In
this regard, human pancreatic cancer cells seem to express
COX-2 preferentially in a perinuclear localization [50]. 15-
deoxy-Δ12,14-prostaglandinJ2 (15-PGJ2),anonenzymatically
formed dehydration product of PGD2, is detectable in
COX-2 expressing human pancreatic cancer cells (own
observation) and able to activate PPAR-γ in these cells
[42]. Furthermore, a selective COX-2 inhibitor at a con-
centration that inhibits COX-2 activity and consequently
prostanoid production reduces PPAR-γ activity, presumably
by decreasing the levels of cyclopentenone prostaglandins
(own observation).
3.2. COXsubstratesasPPAR-γ activators
Certain polyunsaturated fatty acids (PUFAs) (e.g., arachi-
donicacid(AA;20:4 n−6)andeicosapentaenoicacid(EPA;
20:5 n−3))aresubstratesforCOXenzymesandalsoknown
PPAR-γ ligands [51]. Both PUFAs are released from the sn-
2 position of major membrane phospholipids by phospho-
lipase A2 (PLA2) enzymes, particularly by the cytoplasmic
PLA2, which upon activation seems to preferentially locate
to the nuclear membrane [52, 53]. Once released, the PUFAs
can be metabolized by COX enzymes or enter the nucleus
to activate PPAR-γ. Our own studies demonstrated that
EPA decreased the growth of human pancreatic cancer cells
through COX-2 dependent and independent mechanisms
(manuscript in press). The COX-2 independent mechanism
involved activation of PPAR-γ by EPA as the growth-
inhibitory eﬀect of EPA was abolished by a pharmacological
PPAR-γ antagonist. Furthermore, EPA and to a lesser extent
AA can activate PPAR-γ transcriptional activity in human
pancreatic cancer cells (own observation). This eﬀect is less
pronounced in pancreatic cancer cells that express COX-2
presumably because EPA is rapidly metabolized by COX-2 in
these cells. The overall eﬃcacy of PUFAs to activate PPAR-γ
may therefore be dependent on the cellular expression and
activity of COX-2.
3.3. COXinhibitorsasPPAR-γ activators
In addition to COX-2 substrates and products, certain
nonselective and selective COX-2 inhibitors have also been
shown to activate PPAR-γ independent of their ability
to inhibit COX-2 enzymatic activity [54], although the
precise molecular mechanisms are still unknown. There is a
compellingevidencetodaythattheinducibleCOX-2isoform
plays an important role in pancreatic cancer development
and growth and that selective COX-2 inhibitors may be
eﬃcacious for pancreatic cancer prevention and therapy
[50]. Our own studies demonstrated that dietary intake of
a selective COX-2 inhibitor delayed the progression of rec-
ognized pancreatic cancer precursor lesions in a genetically
engineered mouse model of pancreatic cancer development
[55]. Furthermore, a selective COX-2 inhibitor decreased
the growth of COX-2 positive human pancreatic cancers
in a xenograft mouse model by induction of apoptosis
in cancer cells and by inhibition of tumor angiogenesis
[42]. In contrast, the selective COX-2 inhibitor enhanced
the growth of xenografted human pancreatic cancers that
lacked or had very little COX-2 protein expression. This
tumor-promoting eﬀect was associated with an increase
in intratumoral VEGF levels and tumor angiogenesis [42].
Additional studies showed that the tumor-enhancing eﬀect
oftheselectiveCOX-2inhibitorinCOX-2negativeorweakly
COX-2 expressing human pancreatic cancers was abolished
by GW9662, an irreversible pharmacological PPAR-γ antag-
onist,suggestingbiologicallyimportantinteractionsbetween
the COX-2 inhibitor and PPAR-γ [42]. Further studies
demonstrating enhanced PPAR-γ binding activity in tumors
that were treated with a selective COX-2 inhibitor conﬁrmed
that interaction [42]. The ﬁndings obtained in vivo were4 PPAR Research
corroborated by in vitro experiments. Human pancreatic
cancer cells treated with relatively high concentrations of
selective COX-2 inhibitors showed an increased production
and secretion of VEGF, which was inhibited by a pharmaco-
logical PPAR-γ antagonist and a dominant-negative PPAR-γ
receptor [42]. Additionally, the selective COX-2 inhibitor at
that concentration stimulated PPAR-γ transcriptional and
DNA-binding activities [42]. These data clearly indicated
that a biologically signiﬁcant interaction between selective
COX-2 inhibitors and PPAR-γ exists and that activation
of PPAR-γ by these drugs may have detrimental, that is
tumor-promoting, eﬀects on pancreatic cancer growth. It
is important to note that the tumor-promoting eﬀects of
selective COX-2 inhibitors were only observed at relatively
high concentrations (much higher than needed to inhibit
COX-2 enzymatic activity) in tumors that had no or only
very little COX-2 expression [42]. Although the selective
COX-2 inhibitor stimulated VEGF production by pancreatic
cancer cells through a PPAR-γ mediated mechanism also in
COX-2 expressing pancreatic cancers, the potential proan-
giogenic and tumor-promoting eﬀect in COX-2 positive
cancers was masked by a signiﬁcant reduction of COX-2
generated proangiogenic and protumorigenic prostanoids
[42].
4. CONCLUSION
While several in vitro studies demonstrate that PPAR-γ acti-
vation decreases pancreatic cancer cell growth, the ﬁnding
that PPAR-γ ligands can stimulate VEGF production by
pancreatic cancer cells raises serious concerns that PPAR-γ
activation in vivo may lead to enhanced angiogenesis and
tumor growth. Further detailed studies using pancreatic
cancer animal models and speciﬁc PPAR-γ ligands are neces-
sary to evaluate possible proangiogenic and protumorigenic
propertiesofPPAR-γ activationinvivo.Unfortunately,infor-
mationabouttheroleofPPAR-γ inpancreaticcarcinogenesis
is almost nonexistent. The use of the recently developed
genetically engineered mouse models of pancreatic cancer
development that closely recapitulate our current knowledge
of pancreatic cancer development on a histological and
genetic level should shed some needed insights into the role
of PPAR-γ in pancreatic carcinogenesis.
There is now clear evidence of a biologically relevant
interaction between the COX and PPAR-γ pathways. Our
data suggest that activation of PPAR-γ by selective and
nonselective COX-2 inhibitors may have tumor-promoting
eﬀectsinvivobyenhancingtumorangiogenesis.Theeﬀectof
COX-2inhibitorsonPPAR-γ activationseemstobeobserved
only at relatively high concentrations of the inhibitors
and the overall biological phenotype of that interaction is
dependent on the cellular expression and activity of the
COX-2 protein. Although the role of PPAR-γ in pancreatic
cancer development and growth has begun to be elucidated
in recent years, a precise knowledge of molecular targets
downstream of PPAR-γ, a more comprehensive elucidation
of PPAR-γ-independent actions of PPAR-γ ligands, and a
detailed understanding of crosstalks between PPAR-γ and
other intracellular signaling pathways seem to be absolutely
necessary and needed to eventually clarify the role of PPAR-γ
in human cancer development and progression.
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